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Von Willebrand factor A (VWA) domains are versatile
protein interaction domains with N and C termini in
close proximity placing spatial constraints on overall
protein structure. The 1.2 A˚ crystal structures of a
collagen VI VWAdomain and a disease-causing point
mutant show C-terminal extensions that place the N
andC termini at opposite ends. This allows a ‘‘beads-
on-a-string’’ arrangement of multiple VWA domains
as observed for ten N-terminal domains of the
collagen VI a3 chain. The extension is linked to the
core domain by a salt bridge and two hydrophobic
patches. Comparison of the wild-type and a
muscular dystrophy-associated mutant structure
identifies a potential perturbation of a protein inter-
action interface and indeed, the secretion of mutant
collagen VI tetramers is affected. Homology
modeling is used to locate a number of disease-
associated mutations and analyze their structural
impact, which will allow mechanistic analysis of
collagen-VI-associated muscular dystrophy pheno-
types.
INTRODUCTION
Von Willebrand factor A (VWA) domains consist of about 200
amino acid residues and act as interaction modules in many
intra- and extracellular proteins, e.g., in copines, integrins, von
Willebrand factor, complement factors B and C2, matrilins, and
collagens (for review, see Whittaker and Hynes, 2002). They
adopt a Rossmann fold with a central b sheet surrounded by
amphipathic a helices (Rossmann et al., 1974). The N- and C-
termini are close to another and the structure is often stabilized
by two terminal cysteine residues that form a disulfide bridge.
VWA domains often contain a highly conserved metal-ion-
dependent adhesion site (MIDAS) motif that is involved in ligand
binding (Lee et al., 1995).
The structures of VWA domains in several proteins have
been determined in the past. Among these, the integrin I
domains, the VWA domains of the von Willebrand factor, and
the complement factor VWA domains are best characterizedStructure 22, 199–208, Fe(for review, see Springer, 2006). On the basis of such structures,
the role of the MIDAS motif in ligand binding has been studied in
detail. In integrin I domains, theMIDASmotif can exist in different
activation states with varying affinities to the ligands. In addition,
a conformational change of the I-domain occurs upon ligand
binding in which the C-terminal a7 helix moves axially toward
the C terminus. Such structural changes have so far not been
described for any other VWA domain. Some VWA domains,
e.g., the von Willebrand factor A3 domain, bind their ligands
via binding sites other than the MIDAS motif (Bienkowska
et al., 1997; Romijn et al., 2001). No structure of a VWA domain
from the collagen phylogenetic branch has yet been solved.
Eight of the 28 known collagens carry VWA domains (collagen
VI, VII, XII, XIV, XX, XXI, XXII, and XXVIII; for review, see Gordon
and Hahn, 2010). Indeed, a large proportion of the VWA domains
present in mouse proteins occur in collagens. The six collagen VI
a chains contain 46 VWA domains, and these are often involved
in ligand binding (Bonaldo et al., 1990; Specks et al., 1992; Wi-
berg et al., 2003).
Collagen VI is a ubiquitously expressed extracellular matrix
protein that forms a structurally unique network of beaded mi-
crofilaments. It is expressed in almost all connective tissues,
often in association with basement membranes. For a long
time, collagen VI was thought to consist of only three chains:
a1, a2, and a3. Recently, three novel chains (a4, a5, and a6)
were identified that are highly homologous to the a3 chain (Fitz-
gerald et al., 2008; Gara et al., 2008). All collagen VI chains
consist of a relatively short triple-helical region as well as of N-
and C-terminal globular structures that are largely made up of
VWA domains (Figure 1). The N termini of the shorter a1 and
a2 chains contain one VWA domain each, whereas the longer
a3, a4, a5, and a6 chains are composed of ten or seven N-termi-
nal VWA domains. At the C terminus, all chains contain two or, in
case of the a5 chain, three VWA domains and additional
domains.
Collagen VI microfibril formation has been studied in mole-
cules made up by the classical chains (Baldock et al., 2003;
Beecher et al., 2011; Engel et al., 1985; Furthmayr et al., 1983).
In a stepwise assembly, the a1, a2, and a3 chains form triple-
helical monomers that then assemble into disulfide-bonded
antiparallel dimers, followed by the alignment of two dimers to
antiparallel tetramers that are also stabilized by disulfide bonds.
After secretion, the tetramers form microfibrils by connecting in
a head-to-head-fashion, resulting in a ‘‘beads-on-a-string’’
appearance. The novel chains are believed to substitute for thebruary 4, 2014 ª2014 Elsevier Ltd 199Open access under CC BY license.
Figure 1. Domain Structure of the Collagen VI Chains
The numbering of the domains represents the order of the N- and C-terminal
domains in each chain. The asterisk indicates the N5 domain of the a3 chain.
Table 1. Data Collection and Refinement Statistics for Collagen
VI a3N5 and R1061Q Mutant
Collagen VI
a3N5
Collagen VI
a3N5 R1061Q
Data Collection
Space group P21 P43212
Unit cell dimensions (A˚) a = 37.7 a and b = 55.1
b = 58.6
c = 39.3 c = 106.9
Resolution (A˚) 36 - 1.2 (1.26-1.2) 38 - 1.2 (1.22-1.2)
No of molecules in
asymmetric unit
1 1
No. of reflections 114,428 (14214)a 353,145 (12,132)
No. of unique reflections 47,672 (6,693) 53,401 (3,739)
Multiplicity 2.4 (2.1) 6.6 (3.2)
Completeness (%) 97 (93.8) 99.7 (96.6)
Rmerge (%)
b 4.5 (17.4) 4 (49)
<I/s(I) > 10.5 (4.5) 19.3 (2.2)
Refinement
No. of reflections for the
work-data setc
45,221 50,607
No. of reflections for the
test-data setb
2,414 2,707
R/Rfree (%) 13.57/16.19 13.88/16.61
No. of atoms protein/water 3,258/236 3,214/215
Rmsd bond length (A˚) 0.009 0.009
Rmsd bond angles () 1.34 1.32
B factors (A˚2)
Protein 14.6 17.7
Waters 29 31.5
For all atoms 15.6 18.6
aValues in parenthesis are for the highest-resolution shell.
bRmerge =
P
hkl
P
ijIi-Ij/
P
hkl
P
ijIij, where Ii and I are the ith and mean
measure of the intensity of reflection hkl.
cRwork =
P
hkl jjFobsj -jFcalcjj/
P
hkljFobsj, where Fobs and Fcalc are the
observed and calculated structure factors, respectively. Rfree is calcu-
lated as for Rwork but from a subset of the data (5%) that were withheld.
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Collagen VI VWA-Domain Structurea3 chain (Gara et al., 2008). The C-terminal collagen VI domains
are important for assembly and microfibril formation (Ball et al.,
2001; Lamande´ et al., 2006; Tooley et al., 2010), but the N-termi-
nal N1–N5 domains have also been shown to be critical for
collagen VI suprastructure (Fitzgerald et al., 2001).
Mutations in the COL6A1, COL6A2, and COL6A3 genes
lead to the musculoskeletal diseases Bethlem myopathy (BM)
and Ullrich congenital muscular dystrophy (UCMD); (for review,
see Allamand et al., 2011; Lampe and Bushby, 2005). BM
and UCMD represent the mild and the severe end, respectively,
of one clinical spectrum whose hallmarks include proximal
muscle weakness; variable contractures mostly affecting the
long finger flexors, elbows, and ankles; and unusual skin features
such as hypertrophic scars or keloid formation. In addition,
UCMD patients show early-onset muscle weakness, hypere-
lasticity of distal joints, congenital hip dislocations, and, with
progression of the disease, spinal rigidity, scoliosis, and respira-
tory failure. Mostly, BM is caused by recessive and UCMD by
dominant mutations. However, putative recessive mutations
have also been described for UCMD patients (Lampe et al.,
2005). Mutations causing BM are associated with reduced
collagen VI levels, and in UCMD a complete loss of collagen VI
is often caused by introduction of premature stop codons (Baker
et al., 2005). Missense mutations causing UCMD have also been
described, although the disease mechanism is unclear (Lampe
et al., 2005).
To date, the Leiden open variation database (LOVD; http://
www.dmd.nl) reports 35 missense mutations in the exons
encoding the N-and C-terminal VWA domains of the collagen
a3 chain. One of these missense mutations, R1064Q in human
(R1064Qh) that is located in the N5 domain, was found in an
UCMD patient (Lampe et al., 2005). This domain has also been
shown to be essential for collagen VI microfibril assembly (Fitz-
gerald et al., 2001). To gain insight into the disease-causing
mechanism, we crystallized both the wild-type murine collagen
VI a3N5 domain and the N5 domain carrying the R1061Q muta-
tion (R1061Qm), which corresponds to human R1064Qh. We
studied the impact of the mutation on the secretion of the single
VWA domain and the secretion and assembly of collagen VI
tetramers. The structural information was used to model other
collagen VI VWA domains and to evaluate the impact of known
mutations on the domain structures, thereby providing a basis
for genotype-phenotype analysis.200 Structure 22, 199–208, February 4, 2014 ª2014 Elsevier Ltd OpenRESULTS AND DISCUSSION
Structure Determination of the Collagen VI a3N5
Domain
The murine collagen VI a3N5 domain was crystallized and its
structure solved by molecular replacement at 1.2 A˚ resolution
(Table 1). The crystal asymmetric unit contains one molecule
of collagen VI a3N5 comprising residues E1024–P1219. For
the remaining five residues, S1220–G1224, poorer electron
density precluded unambiguous model building. The structure
has a central six-stranded hydrophobic b sheet flanked on
either side by three amphipathic a helices (Figure 2). Based
on the nomenclature of the von Willebrand factor A2 (vWFA2)
domain (Zhang et al., 2009), b strands and a helices are labeled
b1 to b6 and a1 to a6, respectively. Similarly to other members
of the VWA fold, the a4 helix is well formed, while in the vWFA2
domain the a4 helix is absent (Jakobi et al., 2011; Zhang et al., access under CC BY license.
Figure 2. Structure of Collagen VI a3N5
(A) Ribbon diagram of themurine collagen VI a3N5 domain. b strands and a helices of the VWA fold are labeled b1 to b6 and a1 to a6, respectively, and are colored
in blue. The C-terminal extension (residues N1206-G1224) is shown in orange.
(B) Same as (A) but rotated by 90.
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Collagen VI VWA-Domain Structure2009). Like most of the collagen VI VWA domains, the a3N5
domain does not contain a conserved MIDAS motif. The
collagen VI a3N5 domain structure is the first solved structure
of a collagen VWA domain and differs from other VWA domains
in having an extended C-terminal region comprising residues
N1206–G1224 (Figure 2). The C-terminal extension comprises
a short a helix approximately at right angles with helix a6
followed by an extended region that cradles between the a4
and a5 helices of the N5 domain (Figure 2B). Closer examina-
tion of the structure in this region shows that the extension is
linked to the core domain by a salt bridge formed by residue
R1207 from the C-terminal extension and E1024 from the
core domain (Figure 3). Furthermore, residues L1210 and
L1213 pack into a hydrophobic patch (patch 1; Figure 3, dark
blue) formed by the residues P1130, L1132, V1158, and
L1205 from the core domain, and a second hydrophobic patch
(patch 2; Figure 3, light blue) is created by the side chains
F1177, I1178, and P1179 from the core domain, which is buried
by P1215 and I1216 from the C-terminal extension (Figure 3). In
addition, residue I1216 also forms a hydrogen bond to the
backbone carbonyl oxygen of residues I1178. The last two res-
idues of the extension showing unique electron density, resi-
dues L1217 and P1219, interact with a hydrophobic ladder
created by the long hydrophobic portions of the side chains
of residues R1146, V1150, and K1153 of the a4 helix (Figure 3,
green). As a result, the N and C termini are at opposite sides of
the domain, which allows the formation of beads-on-a-string
assemblies of multiple domains. All previously reported VWA
domains have their N and C termini in close proximity at the
same side of the protein. For a number of VWA domains, N-Structure 22, 199–208, Feand C-terminal cysteine residues form disulfide bridges that
close and stabilize the structure.
The C-terminal extension observed here allows a near-linear
arrangement of the adjacent VWA domain in the collagen VI a3
chain. This is in good agreement with the domain arrangement
in collagen VI (Figure 1) and the observed extended structure
of the N9-N1 fragment of collagen VI a3 (Beecher et al., 2011).
Analysis of the Ca atom B factors shows that the C-terminal
extension is less ordered than the core of VWA domain (data
not shown), suggesting a degree of plasticity in the arrangement
of the N5-N4 domain pair.
Analysis of the C-Terminal Extension in Tandem VWA
Domains
Regions flanking folded domains are well placed to regulate
domain function by interacting with the adjacent core domain
and/or by constraining the overall architecture of the intact pro-
tein and its complexes. We created homology models of the
a3N2-N10 domains to identify common features of the extended
C-terminal region. The modeled structures are very similar lead-
ing to pairwise root-mean-square deviations (rmsds) of less than
0.6 A˚ with the a3N5 domain. The largest deviations result from
three- or four-amino acid insertions in the a3N7 and a3N10 do-
mains located in the loop prior to the b6 strand and the a6 helix,
respectively. The resulting structures were analyzed for
conserved features of the interactions between the core do-
mains and the C-terminal extensions that were seen in the
a3N5 domain (Figure 3). The interactions between hydrophobic
patch 1 and the C-terminal extension are well conserved for
the a3N2-N9 domains and in a3N10 hydrophobic interactions201bruary 4, 2014 ª2014 Elsevier Ltd Open access under CC BY license.
Figure 3. Analysis of the C-Terminal Extension
Surface representation of the murine collagen VI a3N5 domain combined with
a ribbon representation of the C-terminal extension showing the residues at
the interface with the core domain. The two regions on the core domain that
form hydrophobic contacts with the C-terminal extension are shown in dark
blue and light blue, respectively. Residues in the extension are shown as ball
and sticks. The region that forms contacts with the C-terminal extension via a
ladder is shown in green. The residues forming the salt bridge are presented as
ball and sticks (gray). The lines (yellow) represent the distances in Angstrom.
Structure
Collagen VI VWA-Domain Structureare replaced by charge interactions due to concomitant residue
changes in the core domain and the extension. In contrast, the
residues creating patch 2 are not well conserved. Together
with the sequence variations in the C-terminal extension facing
patch 2, this suggests that the observed interactions in a3N5
are not maintained among the a3N2–N10 domains beyond the
region defined by patch 1.
To further analyze the C-terminal extension, sequence align-
ments of tandem VWA domains were performed (Figure 4). In
murine proteins, there are 38 tandem VWA domains that are
predominantly found in collagen VI. In addition, von Willebrand
factor has two and vitrin, cochlin, and AMACO have one tandem
VWA domain each. The alignments show that the linkers are
highly diverse, probably reflecting the specific structural require-
ments of each connection. A good example of this diversity is
the lack of similarity between the equivalent collagen VI a5N7-
N6 and the collagen VI a6N7-N6 linker and other linkers. Thus,
a comprehensive alignment was not possible, in particular
because of the differing sequences of the C-terminal VWA
domains of the collagen VI chains. Previous phylogenetic anal-
ysis has shown that those VWA domains group to a distinct
branch (Gara et al., 2008). Hence, they were aligned separately202 Structure 22, 199–208, February 4, 2014 ª2014 Elsevier Ltd Openwith the collagen VI a3N5-N4 linker region (Figure 4B). A unique
feature of the C-terminal domains is the presence of cysteine
residues, which may be involved in interchain crosslinking of
the collagen VI chains. Interestingly, a single cysteine residue
is also present in the linkers of vitrin and cochlin and in the linker
between the N10 and the N9 domains and between the N2 and
the N1 domains of the collagen VI a3 chain and between the N2
and the N1 domains of the collagen VI a5 chain. The length of the
linkers varies greatly, with the longest linker occurring between
the A1 and the A2 domain of the von Willebrand factor and the
shortest in AMACO. It is therefore not surprising that direct
interactions between two tandem VWA domains have been
described only for the A1 and the A2 domain of the von
Willebrand factor (Martin et al., 2007). It is also evident that the
linkers between the N-terminal domains of the classic a3 chain
have similar lengths, while those in the collagen VI a4, a5, and
a6 chains are mostly shorter. This may suggest that their
N-terminal string of VWA domains is more compact. Interest-
ingly, in contrast to the a3 chain, the N-terminal VWA domains
of the a4, a5, and a6 chains mostly possess cysteine residues
at the N- and the C terminus which are known to form long range
disulfide bonds in other VWA domains that may restrain their
structure.
Crystal Structure of the Mutated Collagen VI a3N5
Domain R1061Qm
To gain insight into the UCMD causing mechanism of the
R1064Q mutant in human, the equivalent mutation R1061Qm in
mouse was inserted into the murine collagen VI a3N5 domain
by mutagenesis PCR and the crystal structure of the corre-
sponding recombinant protein was determined at 1.2 A˚ resolu-
tion (Table 1). The overall structure of the mutant VWA domain
is very similar to the wild-type collagen VI a3N5 domain (Fig-
ure 5A) with an rmsd of 0.54 A˚. The most significant structural
difference is around the C terminus where the a6 helix of the
mutant has a small angle with respect to the wild-type leading
to a 1.5 A˚ displacement of the helix in the C-terminal extension.
Poor electron density after residue L1213 in the mutant pre-
cluded the unambiguous assignment of the remainder of the
C-terminal extension residues K2014–G2024.
The residue of the R1061Qm mutation is preceding the
beginning of the b2 strand and is located near the N terminus.
Comparison of the wild-type and mutant structures shows that
the side chains of the wild-type arginine and mutant glutamine
are surface exposed and are pointing in approximately opposite
directions while the remainder of the local conformation is the
same (Figure 5B). The crystal packing of the R1061Qm collagen
VI a3N5 domain is different from the wild-type. While the arginine
residue in the wild-type is in close proximity to the a2a3 loop of
the neighboring molecule, the glutamine residue of the R1061Qm
mutant interacts with the C-terminal part of the adjacent mole-
cule (data not shown). The difference in crystal packing is likely
to contribute to the differences between wild-type and mutant
structures in the C-terminal extension. The charge difference in
the mutant and the difference in crystal packing also indicate
the possibility that this mutationmay alter intra- or intermolecular
interactions and therefore disturb the assembly of collagen VI.
Such surface exposed mutations differ from mutations in the
core of VWA domain structures, e.g., the many mutations in access under CC BY license.
Figure 4. Amino Acid Sequence Alignment of the Linker Regions of Tandem VWA Domains in Mouse
The sequences were from the ENSEMBL database and aligned by the Pileup program.
(A) Alignment of the linkers of vonWillebrand factor (vwf), vitrin (vitr), cochlin (coch), and the N-terminal domains of collagen VI a3, a4, a5, and a6. The domains are
indicated by N10-N1.
(B) Alignment of the collagen VI a3N5-N4 linker and the linkers of the C1 and the C2 domains of all six collagen VI chains. Cysteine residues are underlined. Below,
the borders between the linker and the adjacent domains are indicated. Note that the a5N7-N6 and a6N7-N6 could not be aligned to any other linker.
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Collagen VI VWA-Domain Structurethe matrilin-3 VWA domain that cause multiple epiphyseal
dysplasia (MED) due to endoplasmic reticulum (ER) stress and
the unfolded protein response (Cotterill et al., 2005; Leighton
et al., 2007; Nundlall et al., 2010; Otten et al., 2005).
Impact of the R1061Qm Mutation on Secretion and
Assembly of Collagen VI
We studied the influence of the R1061Qm mutation on the
secretion of the single N5 domain and full-length collagen VI
and on assembly of large collagen VI tetramers to explore
potential mechanisms by which the R1061Qm mutation causes
UCMD. Secretion of the single wild-type andmutated N5 domain
was tested by recombinant expression in 293 Epstein-Barr
nuclear antigen (293EBNA) cells (Figure 6A). The wild-type and
the mutated N5 domain were detected in the culture medium
and cell extracts in comparable amounts, indicating that the
surface exposed missense mutation does not lead to retentionStructure 22, 199–208, Feand accumulation of the single VWA domain in the secretory
pathway.
To determine the influence of the R1061Qmmutation on secre-
tion and assembly of full-length collagen VI, the mutation was
introduced into the murine full-length collagen VI a3 chain (N9-
C5 region). The wild-type and the mutated constructs were
used for transfection of SaOS-2 cells, which produce collagen
VI a1 and a2, but not a3, mRNAs (Lamande´ et al., 1998). The
presence of collagen VI monomers and tetramers in the culture
medium and cell lysates of transfected cells was analyzed by
electrophoresis in agarose/polyacrylamide composite gels after
treatment with 2M urea without reducing agents (Figure 6B). Cul-
ture medium of cells with the wild-type and the mutated
construct was harvested at different time points. Decreased
amounts of mutated collagen VI were detected in the cell culture
medium by immunoblot, possibly indicating a slower rate of
secretion. However, the formation of tetramers was not203bruary 4, 2014 ª2014 Elsevier Ltd Open access under CC BY license.
Figure 5. Comparison of Wild-Type and R1061Qm Mutant Collagen VI a3N5 Domains
(A) Ribbon diagram of wild-type (blue, C-terminal extension in orange) and R1061Qm mutant structure (pink).
(B) Expansion of (A) around the location of themutation. The side-chain conformations of arginine and glutamine in position 1061 are shown in blue and pink stick,
respectively.
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Collagen VI VWA-Domain Structureperturbed by expression of the mutated a3 chain. At any given
time, collagen VI tetramers could be detected for both the
wild-type and the mutated protein. Interestingly, in both cell
extract and culture medium of cells transfected with the mutated
construct, an additional band appeared below the monomers.
This probably reflects degradation of the mutated collagen VI
protein with time. It remains unclear if this degradation contrib-
utes to the drastic phenotype that can be observed in UCMD
patients. This disease is often associated with a complete loss
of collagen VI protein in the extracellular matrix (Baker et al.,
2005). However, the missense mutation may also influence
microfibril formation by perturbation of intermolecular inter-
actions or by destabilizing assembled collagen VI proteins. The
fact, that it makes a difference if the mutated domain is
expressed alone or in context of the full-length collagen VI a3
chain indeed makes it likely that inter- and/or intramolecular in-
teractions of the domain are affected.
Disease-Associated Mutations of Collagen VI a3 VWA
Domains
The structure of the collagen VI a3N5 domainwas used to assess
the potential impact of disease-associated mutations (Lampe
et al., 2005) (LOVD; http://www.dmd.nl). The point mutations
were mapped onto the mouse collagen VI a3N5 domain struc-
ture (Figure 7). Themutations are spread throughout the domain,
including surface exposed loops, secondary structure elements,
as well as a series of positions that are part of the protein core.
Homology models of the VWA domains affected by mutations
were analyzed for the potential impact of the mutation. Most of
the mutated side chains are surface exposed (Table 2), suggest-
ing that the disease-causing effect is related to a perturbation of
sites for interactions with other proteins. The solution structure of
the N9-N1 construct of the collagen VI a3 chain suggests a well-204 Structure 22, 199–208, February 4, 2014 ª2014 Elsevier Ltd Open ordered extended conformation with an overall C shape
(Beecher et al., 2011). This implies the presence of a significant
number of domain-domain interfaces that could be perturbed
by surface mutations. In addition, the supramolecular assembly
of the collagen VI tetramer junction (Baldock et al., 2003) sug-
gests further VWA domain interactions between the N-terminal
and C-terminal VWA arrays. Furthermore in native collagen VI
microfibrils, the domains are associated with other proteins
such as decorin, biglycan, and matrilins (Wiberg et al., 2003).
Four mutations affect residues that are buried in the core of
their respective domain (Figure 7 and Table 2). Only G1679E
and L1726R on the human N2 domain lead to significant pertur-
bations in the packing of the protein core, suggesting a destabi-
lization of the protein fold. Interestingly, in earlier studies, these
two mutations were studied using patient samples. The domi-
nant BM-causing G1679E mutation located in the N2 domain
of the collagen VI a3 chain segregated to all affected family
members in a large pedigree. In cell cultures, the ratios of the
a3 to a1 plus a2 chains synthesized by control and patient fibro-
blasts were similar (Pan et al., 1998). However, in a study where
the isolated N2 domain was recombinantly expressed in
293EBNA cells, the secretion of the mutated N2 domain was
severely reduced compared to that of thewild-type domain, indi-
cating that the protein does not fold properly and is degraded in
the ER (Sasaki et al., 2000). Indeed, our improved model of the
N2 domain confirmed that the position of the affected amino
acid residue is located in the b2 strand. The exact mechanism re-
mains unclear, but the G1679E mutation may cause disease
simply by decreasing the amount of properly folded a3 chains
available for collagen VI assembly. It is not clear whether an a3
chain carrying the G1679Emutation would fold at all, as radioim-
munoassays showed a 20%–30% loss of a3 chain in patient
fibroblast medium and cell lysates (Sasaki et al., 2000). Inaccess under CC BY license.
Figure 6. Immunoblot Analysis of Effects of the R1061Qm Mutation on Secretion and Collagen VI Assembly
(A) Untransfected 293EBNA cells (nt) and cells transfected with the wild-type collagen VI a3N5 domain or the N5 domain carrying the R1061Qm mutation were
cultured for 2 days after transfection. Culturemedium and cell extracts were harvested and subjected to electrophoresis on a 12%SDS-polyacrylamide gel under
reducing conditions. The a3N5 domain was detected with a polyclonal antibody against the strep tag. The molecular masses of marker proteins are indicated on
the left.
(B) SaOS-2 cells stably transfected with thewild-type collagen VI a3 chain (N9-C5) or the a3 chain carrying the R1061Qmmutationwere cultured for up to 14 days.
Culture medium was harvested after 4, 7, 9, 11, or 14 days. After 14 days, the cell layer was extracted. Culture medium and cell extracts were analyzed by
electrophoresis on 0.5%agarose/2.4%polyacrylamide composite gels after treatment with 2M urea under nonreducing conditions. a3-chain-containing proteins
were detected with a polyclonal antibody against the a3 C terminus. Collagen VI monomers and tetramers are indicated on the right. The sizes were estimated
from purified collagen VI protein (Gara et al., 2008) that was used as a standard. The asterisk indicates the putative degradation product found for the mutated a3
protein.
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Collagen VI VWA-Domain Structurecontrast, the dominant L1726R mutation that was found in a BM
patient without affected relatives had no detectable effect on
either intracellular or extracellular assembly, and normal
amounts of collagen VI were deposited in the extracellular matrix
(Baker et al., 2007). In the absence of biochemical characteriza-
tion of the patient extracellular matrix and because of the highly
polymorphic nature of collagen VI genes, it is difficult to establish
the pathogenicity of singlemutations (Lampe andBushby, 2005).
The structures reported here show a C-terminal extension
creating the first VWA domain with N and C termini at opposing
sides of the protein rather than the consensus arrangement for
VWA domains that places the termini in close proximity on the
same faceof thedomain. Analysisof apointmutation that is asso-
ciatedwithUCMDshows that the structureof the isolateddomain
that has themutation is essentially the same as thewild-type, but
subtle differences in cellular processing suggest that the muta-
tion affects inter- and/or intramolecular interactions in collagen
VI processing or assembly. The implications of these findings
are important for the understanding of the overall architecture
of VWAdomain containing proteins and the genotype phenotype
relation in collagen VI associatedmuscular dystrophies andmore
generally demonstrates the versatility of domain structures.EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The borders of the collagen VI a3N5 domain were chosen according to the
exon sequence. The identity between the murine and the human sequence
is 85%. The murine sequence was chosen to be able to take advantage of
themouse as amodel organism in future experiments. A DNA fragment encod-Structure 22, 199–208, Februarying the murine collagen VI a3N5 domain with 50-terminal NheI and 30-terminal
BamHI restriction sites was amplified by PCR using the primers 50-CTAGC
TAGCTCAGGTGAAAAGGATGTGGTG-30 (forward) and 50-CGCGGATCCT
TAACCTGCACCTGTTGAGGGC-30 (reverse), respectively. After digestion
with NheI and BamHI, the PCR fragment was cloned into the pBluescript II
KS (+) vector (Stratgene). This plasmid served as a template for a mutagenesis
PCR to insert the R1061Qm mutation using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene) according to the manufacturer’s instructions
(forward: 50-GATGTGGGTCCCGACCAGGTGCGTGTGGCA-30, reverse: 50-
TGCCACACGCACCTGGTCGGGACCCACATC-30). Wild-type and mutated
DNA were digested with NheI and BamHI and cloned into a modified pET
15b expression vector (Novagen) containing an N-terminal One-STrEP-tag
followed by a thrombin cleavage site. Both constructs were sequenced and
used for transformation of E. coli BL21 Rosetta cells (Novagen). Single
colonies were cultured overnight at 37C in 10 ml LB-medium and 50 mg/ml
ampicillin for selection. The overnight cultures were used to inoculate 8 l LB-
medium containing 50 mg/ml ampicillin and the cultures were grown to
A600 = 0.4–0.6 at 37
C. Subsequently, protein expression was induced by add-
ing isopropyl-b-D-1-thiogalactopyranoside (IPTG) to a final concentration of
1 mM and the cultures were incubated overnight at 28C. After harvesting,
the cells were resuspended in 50 ml lysis buffer (20 mM Tris [pH 7.4],
150 mM NaCl) and lysed by sonication. Insoluble material was removed by
centrifugation at 15,000 rpm and 4C and the supernatant applied to a Strep-
tactin column (IBA). After washing with lysis buffer, the recombinant protein
was eluted with the same buffer containing 2.5 mM desthiobiotin. The One-
STrEP-tag was removed by thrombin digestion using a kit (Novagen). Cleaved
protein was separated from thrombin and remaining uncleaved material by
size exclusion chromatography on a Superdex 75 16/60 column. Peak frac-
tions were pooled, analyzed by SDS-PAGE, and concentrated by ultrafiltration
to 14 mg/ml (wild-type) and 15.3 mg/ml (R1061Qm), respectively.
Cell Culture and Transfection
The collagen VI a3N5 domain constructs (wild-type and with R1064Qm-
mutation [see above]) were cut with NheI and BamHI and inserted into a2054, 2014 ª2014 Elsevier Ltd Open access under CC BY license.
Figure 7. Disease-Causing Mutations Are Mapped onto the
Collagen VI a3N5 Domain Structure
Themurine collagen VI a3N5 structure is shown as a blue ribbon. The locations
of mutations from the Leiden database (LOVD; http://www.dmd.nl) as listed in
Table 2 are shown in red and labeled according to their sequence position in
the full-length human collagen VI a3 protein (ADL14511.1).
Table 2. Disease-Associated Mutations of Human Collagen VI a3
VWA Domains
Domain Mutation
Location on
Structure Disease Reference
N10 G141R surface
exposed
unspecified
myopathy
LOVD
N9 I244V buried unspecified
myopathy
LOVD
N8 D491H surface
exposed
unspecified
myopathy
LOVD
T492S surface
exposed
unspecified
myopathy
LOVD
A596S partially
buried
unspecified
myopathy
LOVD
N7 R659H partially
buried
unspecified
myopathy
LOVD
R677H partially
buried
BM Lampe et al., 2005
A807T surface
exposed
unspecified
myopathy
LOVD
A930S surface
exposed
unspecified
myopathy
LOVD
N6 K1014E surface
exposed
BM Lampe et al., 2005
N5 R1064Q surface
exposed
UCMD Lampe et al., 2005
N4 E1386K surface
exposed
BM Lampe et al., 2005
R1395Q surface
exposed
UCMD Lampe et al., 2005
V1364M buried unspecified
myopathy
LOVD
N3 N1467D surface
exposed
BM Lampe et al., 2005
N2 D1674N surface
exposed
UCMD Lampe et al., 2005
G1679E buried BM Lampe et al., 2005
E1724K surface
exposed
unspecified
myopathy
LOVD
L1726R buried BM Baker et al., 2007
K1754R surface
exposed
unspecified
myopathy
LOVD
Structure
Collagen VI VWA-Domain Structuremodified pCEP-Pu vector containing an N-terminal BM-40 signal peptide
followed by a One-STrEP-tag (IBA). The murine collagen VI a3 N9-C5 region
was generated by PCR and cloned with 50-terminal SpeI and 30-terminal
NotI restriction sites using the primers 50-GGACTAGTCTCAGCTGACAT
TATTTTCCTTATT G-30 (forward) and 50-GAATGCGGCCGCTTAAACTGT
TAACTCAGGACTACACATC-30 (reverse). The amplified PCR fragment was
ligated into a modified pcDNA6 vector (Invitrogen) containing an N-terminal
BM40 signal sequence. To insert the R1061Qm mutation, a cDNA fragment
encoding the region between the two internal restriction sites NdeI and SbfI
was amplified by PCR using the primers 50-CCCTAACCACATATGTTAGTG
GAG-30 (forward) and 50-CCTTAGCTCCTGCAGGGCCCCTTC-30 (reverse),
respectively. This fragment was used as a template for a mutagenesis PCR
(see above). The mutated PCR fragment was digested with NdeI and SbfI
and ligated into the collagen VI a3 N9-C5 region and subsequently cloned
into the modified pcDNA6 vector (Invitrogen). The constructs of the wild-
type and mutated N5 domain were used for transfection of 293EBNA cells
and the wild-type and mutated a3 constructs were used for transfection of
the SaOS-2 human osteosarcoma cell line using FuGENE HD transfection
reagent (Promega). Cells were cultured in Dulbecco’s modified Eagle’s
medium containing 10% (v/v) fetal calf serum and 0.5 mg/ml puromycin
(293EBNA) or 5 mg/ml blasticidin S hydrochloride (SaOS-2) for selection. L-
ascorbic acid and L-ascorbic acid 2-phosphate sesquimagnesium salt
hydrate were added to SaOS-2 cells every 1–2 days to a final concentration
of 0.25 mM and 0.45 mM, respectively.
SDS-PAGE, Agarose/Polyacrylamide Composite Gel
Electrophoresis, and Immunoblotting
Cell extracts and culture medium of transfected and nontransfected 293EBNA
cells were reduced with 5% b-mercaptoethanol and subjected to SDS-PAGE
on 12% (w/v) SDS-polyacrylamide gels. Cell extracts and culture medium of
transfected SaOS-2 cells were supplemented with SDS-containing loading
buffer and urea to a final concentration of 2M and subjected to electrophoresis
on 0.5% (w/v) agarose/2.4% (w/v) polyacrylamide composite gels (Peacock
and Dingman, 1968) under nonreducing conditions to analyze collagen VI
assembly. Purified full-length collagen VI protein (a gift from Paolo Bonaldo,
Padova) was used as a size standard on composite gels.
For immunoblots, the proteins were transferred to nitrocellulose. After
blocking with Tris-buffered saline containing 5% milk powder (single N5
domain) or 1% BSA and 5% milk powder (a3 N9-C5), the nitrocellulose
membrane was incubated with an antibody against the strep-tag (gift from Bir-206 Structure 22, 199–208, February 4, 2014 ª2014 Elsevier Ltd Open git Kobbe) to detect the single N5 domain or an affinity-purified antibody
against the murine collagen VI a3 C terminus to detect the a3 N9-C5 region.
Bound antibodies were detected by enhanced chemoluminescence using
peroxidase-conjugated swine anti-rabbit immunoglobulin G (Dako), 3-amino-
phthalhydrazide (1.25 mM), p-coumaric acid (225 mM), and 0.01% H2O2.
Crystallization and Data Collection
Crystallization experiments were performed at room temperature using the
sitting-drop vapor diffusion method. A crystal of collagen VI a3N5 was
observed in 0.1 M sodium cacodylate (pH 6.5), 1 M tri-sodium citrate using
the 0.2:0.1 ratio, whereas a crystal of the R1061Qm mutant was observed in
0.2 M sodium chloride, 0.1 M phosphate/citrate (pH 4.2), 20% w/v PEG
8000 in the 0.1:0.1 ratio. The crystal of collagen VI a3N5 grew to the dimen-
sions of 170 mm 3 100 mm 3 50 mm, whereas crystals of R1061Qm grew to
the dimensions of 100 mm 3 90 mm 3 40 mm in 1 week. All crystals were
cryoprotected with 30% (v/v) glycerol and flash-frozen in liquid nitrogen foraccess under CC BY license.
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Collagen VI VWA-Domain Structurestorage. X-ray diffraction data were collected at 100 K using the beamline ID24
at Diamond (Oxford, UK) at a wavelength of l = 0.97780 with a Pilates 6M
detector.
A complete data set of collagen VI a3N5 was collected to 1.2 A˚ resolution
(0.15 oscillation with 0.2 s exposure time). The data were integrated and pro-
cessed with iMOSFLM (Battye et al., 2011) from the CCP4 (CCP4, 1994) suite.
The crystal belongs to the space group P21 and had unit cell dimensions of a =
37.7, b = 58.6, c = 39.3, alpha = 90, beta = 113, gamma = 90. The Mathews
coefficient is 1.74 and the solvent content is 29.4% with one molecule in the
asymmetric unit.
A complete data set of R1061Qm was collected to 1.2 A˚ resolution (0.15
oscillation with 0.1 s exposure time). The data were integrated and processed
with XIA (Winter, 2010). The crystal belongs to the space group P43212 and had
unit cell dimensions a = 55.1, b = 55.1, c = 106.9, alpha = 90, beta = 90,
gamma = 90. The Mathews coefficient is 1.77 and the solvent content is
30.7% with one molecule in the asymmetric unit.
Structure Determination and Refinement
The structure of VWF A2 (Protein Data Bank code 3GXB) was modified and all
side chain residues pruned to Cb atoms using the program CHAINSAW in
CCP4. The output was used as a search model in PHASER (McCoy et al.,
2007) for the collagen VI a3N5 data set. The structure was built in parts with
ARP/wARP (Langer et al., 2008) and completed with COOT (Emsley and
Cowtan, 2004). The initial refinements were carried out using data to 1.5 A˚ in
PHENIX (Adams et al., 2011). Further refinement rounds were performed using
diffraction data to 1.2 A˚ andmanual rebuilding. Solvent molecules and alterna-
tive conformations were gradually added. A final round of refinement included
anisotropic data.
The mutant structure R1061Qm mutant was solved using PHASER with the
fully refined native structure of collagen VI a3N5. The structurewas refinedwith
PHENIX and model built with COOT (Emsley and Cowtan, 2004). Table 1 sum-
marizes data collection and refinement statistics. Both crystal structures were
validated with Molprobity (Chen et al., 2010). The Ramachandran plot for the
collagen VI a3N5 structure (R1061Qm) shows that 92.1 (93.2) % of non-Gly
and non-Pro residues are in the most favored regions and 6.7 (5.6) % are in
the additionally allowed regions. The remaining 1.2% is due to two residues,
R1061 and S1070, which are in the generously allowed regions.
Homology Modeling
Homology modeling of the human collagen VI VWA domains was carried out
using Modeler 4.12 (Sali and Blundell, 1993) in UCSF Chimera 1.6.1 (Pettersen
et al., 2004) using the mouse collagen VI a3N5 as the template structure. The
modeling was restricted to the N-terminal domains, N10 to N2, from collagen
VI a3, because the sequence identity of the template sequencewas sufficiently
high (>29%). Somewhat lower sequence identities were observed for the
C-terminal domains and VWA domains from other collagen VI chains. For
each domain, five models were generated and the one with the lowest normal-
ized discrete optimized protein energy (zDOPE) score was retained for energy
minimization. zDOPE scores were less than 1.0 and a small number of
clashes suggested reasonable protein structures. The rmsds with the target
structure were less than 0.6 A˚, indicating a close resemblance of modeled
VWA domains with the collagen VI a3N5 domain. The point mutations listed
in Table 2 were introduced in the respective modeled domains and their
surface exposure and packing inspected. The mutations were classified as
either surface exposed, partially buried, or buried depending on whether the
side chains of the mutant residue were fully exposed to the solvent or not. In
all cases, the mutations of buried residues introduced significant packing per-
turbations, suggesting that they would perturb the fold of the respective
domain.
Sequence Alignment
Sequences were downloaded from the ENSEMBL mouse genome browser
(GRCm38). For the alignments, the complete preceding VWA domain, the
linker region, and the beginning of the next VWA domain were used. Multiple
sequence alignments were performed using the PILEUP program of the WIS-
CONSIN PACKAGE version 10.3 (Accelrys), using the parameters GapWeight:
6 and GapLengthWeight: 1 for Figure 5A and GapWeight: 2 and GapLength-Structure 22, 199–208, FeWeight: 1 for Figure 5B. Figureswere preparedwith the BOXSHADE v3.21 pro-
gram. In the figure, only the linker region and adjacent sequences are shown.
Graphical Representation of Structures
Figures 2, 3, 4, and 7 were generated using UCSF Chimera 1.6.1 (Pettersen
et al., 2004).
ACCESSION NUMBERS
The coordinates and the structure factors of murine collagen VI a3N5 and
R1061Q have been deposited in the RCSB Protein Data Bank with accession
numbers 4IGI and 4IHK, respectively.
ACKNOWLEDGMENTS
This work was supported by the Deutsche Forschungsgemeinschaft
(WA1338/2-6, SFB829) and Boehringer Ingelheim Fonds. J.M.W. would like
to acknowledge support from the Wellcome Trust (WT090678/7/09/2). We
gratefully acknowledge support from Stuart Findlow at the Southampton
Centre for Biological NMR and access to the National NMR Facility at NIMR
(Mill Hill). We thank the synchrotron Radiation Facility (DIAMOND), Oxford,
UK for beam time and excellent support.
Received: December 23, 2012
Revised: May 27, 2013
Accepted: November 7, 2013
Published: December 12, 2013
REFERENCES
Adams, P.D., Afonine, P.V., Bunko´czi, G., Chen, V.B., Echols, N., Headd, J.J.,
Hung, L.W., Jain, S., Kapral, G.J., Grosse Kunstleve, R.W., et al. (2011). The
Phenix software for automated determination of macromolecular structures.
Methods 55, 94–106.
Allamand, V., Brin˜as, L., Richard, P., Stojkovic, T., Quijano-Roy, S., and
Bonne, G. (2011). ColVI myopathies: where do we stand, where do we go?
Skelet. Muscle 1, 30.
Baker, N.L., Mo¨rgelin, M., Peat, R., Goemans, N., North, K.N., Bateman, J.F.,
and Lamande´, S.R. (2005). Dominant collagen VI mutations are a common
cause of Ullrich congenital muscular dystrophy. Hum. Mol. Genet. 14,
279–293.
Baker, N.L., Mo¨rgelin, M., Pace, R.A., Peat, R.A., Adams, N.E., Gardner,
R.J.M., Rowland, L.P., Miller, G., De Jonghe, P., Ceulemans, B., et al.
(2007). Molecular consequences of dominant Bethlem myopathy collagen VI
mutations. Ann. Neurol. 62, 390–405.
Baldock, C., Sherratt, M.J., Shuttleworth, C.A., and Kielty, C.M. (2003). The
supramolecular organization of collagen VI microfibrils. J. Mol. Biol. 330,
297–307.
Ball, S.G., Baldock, C., Kielty, C.M., and Shuttleworth, C.A. (2001). The role of
the C1 and C2 a-domains in type VI collagen assembly. J. Biol. Chem. 276,
7422–7430.
Battye, T.G., Kontogiannis, L., Johnson, O., Powell, H.R., and Leslie, A.G.
(2011). iMOSFLM: a new graphical interface for diffraction-image processing
with MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 67, 271–281.
Beecher, N., Roseman, A.M., Jowitt, T.A., Berry, R., Troilo, H., Kammerer,
R.A., Shuttleworth, C.A., Kielty, C.M., and Baldock, C. (2011). Collagen VI,
conformation of A-domain arrays and microfibril architecture. J. Biol. Chem.
286, 40266–40275.
Bienkowska, J., Cruz, M., Atiemo, A., Handin, R., and Liddington, R. (1997).
The von willebrand factor A3 domain does not contain a metal ion-dependent
adhesion site motif. J. Biol. Chem. 272, 25162–25167.
Bonaldo, P., Russo, V., Bucciotti, F., Doliana, R., and Colombatti, A. (1990).
Structural and functional features of the alpha 3 chain indicate a bridging
role for chicken collagen VI in connective tissues. Biochemistry 29, 1245–
1254.207bruary 4, 2014 ª2014 Elsevier Ltd Open access under CC BY license.
Structure
Collagen VI VWA-Domain StructureCCP4 (Collaborative Computational Project, Number 4) (1994). The CCP4
suite: programs for protein crystallography. Acta Crystallogr. D Biol.
Crystallogr. 50, 760–763.
Chen, V.B., Arendall, W.B., 3rd, Headd, J.J., Keedy, D.A., Immormino, R.M.,
Kapral, G.J., Murray, L.W., Richardson, J.S., and Richardson, D.C. (2010).
MolProbity: all-atom structure validation for macromolecular crystallography.
Acta Crystallogr. D Biol. Crystallogr. 66, 12–21.
Cotterill, S.L., Jackson, G.C., Leighton, M.P., Wagener, R., Ma¨kitie, O., Cole,
W.G., and Briggs, M.D. (2005). Multiple epiphyseal dysplasia mutations in
MATN3 cause misfolding of the A-domain and prevent secretion of mutant
matrilin-3. Hum. Mutat. 26, 557–565.
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular
graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132.
Engel, J., Furthmayr, H., Odermatt, E., von der Mark, H., Aumailley, M.,
Fleischmajer, R., and Timpl, R. (1985). Structure and macromolecular organi-
zation of type VI collagen. Ann. N Y Acad. Sci. 460, 25–37.
Fitzgerald, J., Mo¨rgelin, M., Selan, C.,Wiberg, C., Keene, D.R., Lamande´, S.R.,
and Bateman, J.F. (2001). The N-terminal N5 subdomain of the alpha 3(VI)
chain is important for collagen VI microfibril formation. J. Biol. Chem. 276,
187–193.
Fitzgerald, J., Rich, C., Zhou, F.H., and Hansen, U. (2008). Three novel
collagen VI chains, alpha4(VI), alpha5(VI), and alpha6(VI). J. Biol. Chem. 283,
20170–20180.
Furthmayr, H., Wiedemann, H., Timpl, R., Odermatt, E., and Engel, J. (1983).
Electron-microscopical approach to a structural model of intima collagen.
Biochem. J. 211, 303–311.
Gara, S.K., Grumati, P., Urciuolo, A., Bonaldo, P., Kobbe, B., Koch, M.,
Paulsson, M., and Wagener, R. (2008). Three novel collagen VI chains with
high homology to the alpha3 chain. J. Biol. Chem. 283, 10658–10670.
Gordon, M.K., and Hahn, R.A. (2010). Collagens. Cell Tissue Res. 339,
247–257.
Jakobi, A.J., Mashaghi, A., Tans, S.J., and Huizinga, E.G. (2011). Calcium
modulates force sensing by the von Willebrand factor A2 domain. Nat.
Commun. 2, 385.
Lamande´, S.R., Sigalas, E., Pan, T.C., Chu, M.L., Dziadek, M., Timpl, R., and
Bateman, J.F. (1998). The role of the alpha3(VI) chain in collagen VI assembly.
Expression of an alpha3(VI) chain lacking N-terminal modules N10-N7 restores
collagen VI assembly, secretion, and matrix deposition in an alpha3(VI)-defi-
cient cell line. J. Biol. Chem. 273, 7423–7430.
Lamande´, S.R., Mo¨rgelin, M., Adams, N.E., Selan, C., and Allen, J.M. (2006).
The C5 domain of the collagen VI alpha3(VI) chain is critical for extracellular
microfibril formation and is present in the extracellular matrix of cultured cells.
J. Biol. Chem. 281, 16607–16614.
Lampe, A.K., and Bushby, K.M.D. (2005). Collagen VI related muscle disor-
ders. J. Med. Genet. 42, 673–685.
Lampe, A.K., Dunn, D.M., von Niederhausern, A.C., Hamil, C., Aoyagi, A.,
Laval, S.H., Marie, S.K., Chu, M.L., Swoboda, K., Muntoni, F., et al. (2005).
Automated genomic sequence analysis of the three collagen VI genes: appli-
cations to Ullrich congenital muscular dystrophy and Bethlem myopathy.
J. Med. Genet. 42, 108–120.
Langer, G., Cohen, S.X., Lamzin, V.S., and Perrakis, A. (2008). Automated
macromolecular model building for X-ray crystallography using ARP/wARP
version 7. Nat. Protoc. 3, 1171–1179.
Lee, J.O., Rieu, P., Arnaout, M.A., and Liddington, R. (1995). Crystal structure
of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18). Cell 80,
631–638.
Leighton, M.P., Nundlall, S., Starborg, T., Meadows, R.S., Suleman, F.,
Knowles, L., Wagener, R., Thornton, D.J., Kadler, K.E., Boot-Handford, R.P.,
and Briggs, M.D. (2007). Decreased chondrocyte proliferation and dysregu-
lated apoptosis in the cartilage growth plate are key features of amurinemodel
of epiphyseal dysplasia caused by a matn3 mutation. Hum. Mol. Genet. 16,
1728–1741.208 Structure 22, 199–208, February 4, 2014 ª2014 Elsevier Ltd Open aMartin, C., Morales, L.D., and Cruz, M.A. (2007). Purified A2 domain of von
Willebrand factor binds to the active conformation of von Willebrand factor
and blocks the interaction with platelet glycoprotein Ibalpha. J. Thromb.
Haemost. 5, 1363–1370.
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C.,
and Read, R.J. (2007). Phaser crystallographic software. J. Appl. Cryst. 40,
658–674.
Nundlall, S., Rajpar, M.H., Bell, P.A., Clowes, C., Zeeff, L.A.H., Gardner, B.,
Thornton, D.J., Boot-Handford, R.P., and Briggs, M.D. (2010). An unfolded
protein response is the initial cellular response to the expression of mutant
matrilin-3 in a mouse model of multiple epiphyseal dysplasia. Cell Stress
Chaperones 15, 835–849.
Otten, C., Wagener, R., Paulsson, M., and Zaucke, F. (2005). Matrilin-3 muta-
tions that cause chondrodysplasias interfere with protein trafficking while a
mutation associated with hand osteoarthritis does not. J. Med. Genet. 42,
774–779.
Pan, T.C., Zhang, R.Z., Pericak-Vance, M.A., Tandan, R., Fries, T., Stajich,
J.M., Viles, K., Vance, J.M., Chu, M.L., and Speer, M.C. (1998). Missense
mutation in a von Willebrand factor type A domain of the alpha 3(VI) collagen
gene (COL6A3) in a family with Bethlem myopathy. Hum. Mol. Genet. 7,
807–812.
Peacock, A.C., and Dingman, C.W. (1968). Molecular weight estimation and
separation of ribonucleic acid by electrophoresis in agarose-acrylamide
composite gels. Biochemistry 7, 668–674.
Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M.,
Meng, E.C., and Ferrin, T.E. (2004). UCSF Chimera—a visualization system
for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612.
Romijn, R.A.P., Bouma, B., Wuyster, W., Gros, P., Kroon, J., Sixma, J.J., and
Huizinga, E.G. (2001). Identification of the collagen-binding site of the von
Willebrand factor A3-domain. J. Biol. Chem. 276, 9985–9991.
Rossmann, M.G., Moras, D., and Olsen, K.W. (1974). Chemical and biological
evolution of nucleotide-binding protein. Nature 250, 194–199.
Sali, A., and Blundell, T.L. (1993). Comparative protein modelling by satisfac-
tion of spatial restraints. J. Mol. Biol. 234, 779–815.
Sasaki, T., Hohenester, E., Zhang, R.Z., Gotta, S., Speer, M.C., Tandan, R.,
Timpl, R., and Chu, M.L. (2000). A Bethlem myopathy Gly to Glu mutation in
the von Willebrand factor A domain N2 of the collagen alpha3(VI) chain inter-
feres with protein folding. FASEB J. 14, 761–768.
Specks, U., Mayer, U., Nischt, R., Spissinger, T., Mann, K., Timpl, R., Engel, J.,
and Chu, M.L. (1992). Structure of recombinant N-terminal globule of type VI
collagen alpha 3 chain and its binding to heparin and hyaluronan. EMBO J.
11, 4281–4290.
Springer, T.A. (2006). Complement and the multifaceted functions of VWA and
integrin I domains. Structure 14, 1611–1616.
Tooley, L.D., Zamurs, L.K., Beecher, N., Baker, N.L., Peat, R.A., Adams, N.E.,
Bateman, J.F., North, K.N., Baldock, C., and Lamande´, S.R. (2010). Collagen
VI microfibril formation is abolished by an alpha2(VI) vonWillebrand factor type
A domain mutation in a patient with Ullrich congenital muscular dystrophy.
J. Biol. Chem. 285, 33567–33576.
Whittaker, C.A., and Hynes, R.O. (2002). Distribution and evolution of von
Willebrand/integrin A domains: widely dispersed domains with roles in cell
adhesion and elsewhere. Mol. Biol. Cell 13, 3369–3387.
Wiberg, C., Klatt, A.R., Wagener, R., Paulsson, M., Bateman, J.F., Heinega˚rd,
D., and Mo¨rgelin, M. (2003). Complexes of matrilin-1 and biglycan or decorin
connect collagen VI microfibrils to both collagen II and aggrecan. J. Biol.
Chem. 278, 37698–37704.
Winter, G. (2010). xia2: an expert system for macromolecular crystallography
data reduction. J. Appl. Crystallogr. 43, 186–190.
Zhang, Q., Zhou, Y.F., Zhang, C.Z., Zhang, X.H., Lu, C.F., and Springer, T.A.
(2009). Structural specializations of A2, a force-sensing domain in the ultra-
large vascular protein von Willebrand factor. Proc. Natl. Acad. Sci. USA 106,
9226–9231.ccess under CC BY license.
